Clinical Trial Update: Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of auranofin and sirolimus in advanced solid tumors including recurrent non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Auranofin (auranofin)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Non-small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: WITHDRAWN